Keyword Analysis & Research: idsa guidelines covid

idsociety.org

https://www.idsociety.org/practice-guideline/covid-19-guideline-serology?n=@

WebApr 11, 2020 · Recommendation 15(UPDATED 2/22/2023): Among ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease who have no other treatment options*, the IDSA guideline panel suggests FDA-qualified high-titer …

DA: 97 PA: 52 MOZ Rank: 8

nih.gov

https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/hospitalized-adults--therapeutic-management/

Table 2b. Therapeutic Management of Hospitalized Adults With COVID-19Patients Who Are Hospitalized for Reasons Other Than COVID-19 and Who Do Not Require Supplemental OxygenPatients Who Are Hospitalized for COVID-19 and Who Do Not Require Supplemental OxygenPatients Who Require Conventional OxygenPatients Who Require High-Flow Nasal Cannula Oxygen or Noninvasive VentilationPatients Who Require Mechanical Ventilation or Extracorporeal Membrane OxygenationTable 2c. Dosing Regimens for the Drugs Recommended in Table 2bReferencesRecommendations•The Panel recommends using remdesivir for the treatment of COVID-19 in patients who do not require supplemental oxygen and who are immunocompromised (BIIb) and for other patients who are at high risk of progressing to severe disease (BIII). •Remdesivir should be administered for 5 days or until hospital discharge, whichever comes first. Recommendations•The Panel recommends using remdesivir for the treatment of COVID-19 in patients who do not require supplemental oxygen and who are immunocompromised (BIIb) and for other patients who are at high risk of progressing to severe disease (BIII).  •Remdesivir should be administered for 5 days or until hospital discharge, whichever comes first.The rationale for using remdesivir in high-risk patients is based on several lines of evidence. In a trial conducted predominantly among hospitalized patients with COVID-19 who were not receiving supplemental oxygen at enrollment, a 5-day course of remdesivir was associated with greater cl…

Recommendations•The Panel recommends using remdesivir for the treatment of COVID-19 in patients who do not require supplemental oxygen and who are immunocompromised (BIIb) and for other patients who are at high risk of progressing to severe disease (BIII). 

•Remdesivir should be administered for 5 days or until hospital discharge, whichever comes first.The rationale for using remdesivir in high-risk patients is based on several lines of evidence. In a trial conducted predominantly among hospitalized patients with COVID-19 who were not receiving supplemental oxygen at enrollment, a 5-day course of remdesivir was associated with greater cl…

DA: 19 PA: 55 MOZ Rank: 25